Compare REYN & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REYN | TGTX |
|---|---|---|
| Founded | 1947 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.9B |
| IPO Year | 2019 | 2008 |
| Metric | REYN | TGTX |
|---|---|---|
| Price | $24.46 | $29.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $25.43 | ★ $50.67 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-29-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | 1.43 | ★ 2.77 |
| Revenue | ★ $3,756,000,000.00 | $2,785,000.00 |
| Revenue This Year | $2.04 | $90.97 |
| Revenue Next Year | $1.82 | $45.74 |
| P/E Ratio | $17.30 | ★ $10.81 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.91 | $25.37 |
| 52 Week High | $26.25 | $46.48 |
| Indicator | REYN | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.10 | 48.55 |
| Support Level | $23.49 | $27.25 |
| Resistance Level | $24.85 | $30.00 |
| Average True Range (ATR) | 0.48 | 1.11 |
| MACD | 0.12 | 0.13 |
| Stochastic Oscillator | 74.11 | 47.18 |
Reynolds Consumer Products Inc is a provider of household products. The firm is engaged in the production and sales of cooking products, waste and storage products, and tableware. It operates through four reportable segments namely, Reynolds Cooking and Baking, Hefty Waste and Storage, Hefty Tableware, and Presto Products. Reynolds Cooking and Baking segment produce branded and store brand aluminum foil, disposable aluminum pans, parchment paper, freezer paper, wax paper, butcher paper, plastic wrap, baking cups, oven bags and slow cooker liners.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.